Mie Rizig,Sara Bandres-Ciga,Mary B Makarious,Oluwadamilola Ojo,Peter Wild Crea,Oladunni Abiodun,Kristin S Levine,Sani Abubakar,Charles Achoru,Dan Vitale,Olaleye Adeniji,Osigwe Agabi,Mathew J Koretsky,Uchechi Agulanna,Deborah A Hall,Rufus Akinyemi,Tao Xie,Mohammed Ali,Ejaz A Shamim,Ifeyinwa Ani-Osheku,Mahesh Padmanaban,Owotemu Arigbodi,David G Standaert,Abiodun Bello,Marissa Dean,Cyril Erameh,Inas Elsayed,Temitope Farombi,Olaitan Okunoye,Michael Fawale,Kimberley J Billingsley,Frank Imarhiagbe,Pilar Alvarez Jerez,Emmanuel Iwuozo,Breeana Baker,Morenikeji Komolafe,Laksh Malik,Paul Nwani,Kensuke Daida,Ernest Nwazor,Abigail Miano-Burkhardt,Yakub Nyandaiti,Zih-Hua Fang,Yahaya Obiabo,Jillian H Kluss,Olanike Odeniyi,Dena Hernandez,Francis Odiase,Nahid Tayebi,Francis Ojini,Ellen Sidranksy,Gerald Onwuegbuzie,Andrea M D'Souza,Godwin Osaigbovo,Bahafta Berhe,Nosakhare Osemwegie,Xylena Reed,Olajumoke Oshinaike,Hampton Leonard,Folajimi Otubogun,Chelsea X Alvarado,Shyngle Oyakhire,Simon Ozomma,Sarah Samuel,Funmilola Taiwo,Kolawole Wahab,Yusuf Zubair,Hirotaka Iwaki,Jonggeol Jeffrey Kim,Huw R Morris,John Hardy,Mike Nalls,Karl Heilbron,Lucy Norcliffe-Kaufmann,Disease Research Network, International Parkinson’s Disease Genomics Consortium - Africa (IPDGC Africa), Black and African American Connections to Parkinson’s Disease (BLAAC PD) Study Group, the 23andMe Research Team,Cornelis Blauwendraat,Henry Houlden,Andrew Singleton,Njideka Okubadejo

Abstract:Background: Understanding the genetic mechanisms underlying diseases in ancestrally diverse populations is a critical step towards the realization of the global application of precision medicine. The African and African admixed populations enable mapping of complex traits given their greater levels of genetic diversity, extensive population substructure, and distinct linkage disequilibrium patterns. Methods: Here we perform a comprehensive genome-wide assessment of Parkinson's disease (PD) in 197,918 individuals (1,488 cases; 196,430 controls) of African and African admixed ancestry, characterizing population-specific risk, differential haplotype structure and admixture, coding and structural genetic variation and polygenic risk profiling. Findings: We identified a novel common risk factor for PD and age at onset at the GBA1 locus (risk, rs3115534-G; OR=1.58, 95% CI = 1.37 - 1.80, P=2.397E-14; age at onset, BETA =-2.004, SE =0.57, P = 0.0005), that was found to be rare in non-African/African admixed populations. Downstream short- and long-read whole genome sequencing analyses did not reveal any coding or structural variant underlying the GWAS signal. However, we identified that this signal mediates PD risk via expression quantitative trait locus (eQTL) mechanisms. While previously identified GBA1 associated disease risk variants are coding mutations, here we suggest a novel functional mechanism consistent with a trend in decreasing glucocerebrosidase activity levels. Given the high population frequency of the underlying signal and the phenotypic characteristics of the homozygous carriers, we hypothesize that this variant may not cause Gaucher disease. Additionally, the prevalence of Gaucher's disease in Africa is low. Interpretation: The present study identifies a novel African-ancestry genetic risk factor in GBA1 as a major mechanistic basis of PD in the African and African admixed populations. This striking result contrasts to previous work in Northern European populations, both in terms of mechanism and attributable risk. This finding highlights the importance of understanding population-specific genetic risk in complex diseases, a particularly crucial point as the field moves toward precision medicine in PD clinical trials and while recognizing the need for equitable inclusion of ancestrally diverse groups in such trials. Given the distinctive genetics of these underrepresented populations, their inclusion represents a valuable step towards insights into novel genetic determinants underlying PD etiology. This opens new avenues towards RNA-based and other therapeutic strategies aimed at reducing lifetime risk. Evidence before this study: Our current understanding of Parkinson's disease (PD) is disproportionately based on studying populations of European ancestry, leading to a significant gap in our knowledge about the genetics, clinical characteristics, and pathophysiology in underrepresented populations. This is particularly notable in individuals of African and African admixed ancestries. Over the last two decades, we have witnessed a revolution in the research area of complex genetic diseases. In the PD field, large-scale genome-wide association studies in the European, Asian, and Latin American populations have identified multiple risk loci associated with disease. These include 78 loci and 90 independent signals associated with PD risk in the European population, nine replicated loci and two novel population-specific signals in the Asian population, and a total of 11 novel loci recently nominated through multi-ancestry GWAS efforts.Nevertheless, the African and African admixed populations remain completely unexplored in the context of PD genetics. Added value of this study: To address the lack of diversity in our research field, this study aimed to conduct the first genome-wide assessment of PD genetics in the African and African admixed populations. Here, we identified a genetic risk factor linked to PD etiology, dissected African-specific differences in risk and age at onset, characterized known genetic risk factors, and highlighted the utility of the African and African admixed risk haplotype substructure for future fine-mapping efforts. We identified a novel disease mechanism via expression changes consistent with decreased GBA1 activity levels. Future large scale single cell expression studies should investigate the neuronal populations in which expression differences are most prominent. This novel mechanism may hold promise for future efficient RNA-based therapeutic strategies such as antisense oligonucleotides or short interfering RNAs aimed at preventing and decreasing disease risk. We envisage that these data generated under the umbrella of the Global Parkinson's Genetics Program (GP2) will shed light on the molecular mechanisms involved in the disease process and might pave the way for future clinical trials and therapeutic interventions. This work represents a valuable resource in an underserved population, supporting pioneering research within GP2 and beyond. Deciphering causal and genetic risk factors in all these ancestries will help determine whether interventions, potential targets for disease modifying treatment, and prevention strategies that are being studied in the European populations are relevant to the African and African admixed populations. Implications of all the available evidence: We nominate a novel signal impacting GBA1 as the major genetic risk factor for PD in the African and African admixed populations. The present study could inform future GBA1 clinical trials, improving patient stratification. In this regard, genetic testing can help to design trials likely to provide meaningful and actionable answers. It is our hope that these findings may ultimately have clinical utility for this underrepresented population.

The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia

Genome-wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in Parkinson’s Disease

Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk

Common genetic risk for Parkinson's disease and dysfunction of the endo-lysosomal system

A proteogenomic view of Parkinson’s disease causality and heterogeneity

Genetic risk factors in Parkinson’s disease

Embracing Monogenic Parkinson's Disease: the MJFF Global Genetic PD Cohort.

Understanding Parkinson disease in Spain: Genetic and clinical insights

Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease

Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches

Multimodal analysis of gene expression from postmortem brains and blood identifies synaptic vesicle trafficking genes to be associated with Parkinson’s disease

Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson's Disease in African and African Admixed Populations

Genome-wide determinants of mortality and motor progression in Parkinson's disease

variants cause a phenotypic spectrum from early-onset Parkinson's disease to perinatal lethality by disrupting mitochondrial pathways

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts

Uncovering the genetic basis of Parkinson's disease globally: from discoveries to the clinic

Genetic Insights into Sporadic Parkinson's Disease Pathogenesis

Multimodal Analysis of Gene Expression from Postmortem Brains and Blood Identifies Synaptic Vesicle Trafficking Genes to Be Associated with Parkinson's Disease.

Prioritizing Parkinson's disease risk genes in genome-wide association loci

Novel susceptibility genes and molecular mechanisms identified in relation to mitochondrial dysfunctions in Parkinson’s disease